News | Image Guided Radiation Therapy (IGRT) | September 11, 2019

ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian

Clinicians from 17 hospitals worldwide to present clinical experience with MRIdian MRI-guided radiation therapy

ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian

September 11, 2019 — ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation therapy systems will be featured at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 15-19 in Chicago. The meeting will feature a number of presentations highlighting the capabilities, clinical experience and patient outcomes with ViewRay's MRIdian and MRIdian Linac.

First introduced by ViewRay in 2012, MRI-Guided ROAR (Real-time On-table Adaptive Radiotherapy) represents a new paradigm in cancer treatment, according to the company. It provides clinicians with the ability to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses.

At this year's ASTRO, more than 20 scientific session presentations/posters will highlight the role of MRIdian in cancer treatment, including the value of its MRI-guidance, targeted dose delivery and automated beam gating. With the added clarity provided by MRIdian real-time imaging, physicians are better equipped to account for any motion caused by respiration or other bodily processes and personalize each treatment.

An ASTRO Industry Expert Theater session will feature two talks on the role of MRIdian in the treatment of prostate and pancreatic cancer. The first by Ben Slotman, M.D., Ph.D., from Amsterdam University Medical Centers is titled "MR-Guided Daily Adaptive SBRT for Prostate Cancer - A Phase 2 Prospective Study," and the second by Michael Chuong, M.D., from Miami Cancer Institute, Baptist Health South Florida is titled "MR-Guided SBRT for Pancreas with On-table Adaptation on MRIdian - MCI Experience."

ViewRay's booth will feature presentations from eight MRIdian users covering a wide range of topics and indications. 

For more information: www.viewray.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost